These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986 [TBL] [Abstract][Full Text] [Related]
5. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552 [TBL] [Abstract][Full Text] [Related]
6. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238 [TBL] [Abstract][Full Text] [Related]
7. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. McCarthy EM; Lee RZ; Ní Gabhann J; Smith S; Cunnane G; Doran MF; Howard D; O'Connell P; Kearns G; Jefferies CA Rheumatology (Oxford); 2013 Jul; 52(7):1279-84. PubMed ID: 23479724 [TBL] [Abstract][Full Text] [Related]
8. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders. La DT; Collins CE; Yang HT; Migone TS; Stohl W Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830 [TBL] [Abstract][Full Text] [Related]
9. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Ritterhouse LL; Crowe SR; Niewold TB; Merrill JT; Roberts VC; Dedeke AB; Neas BR; Thompson LF; Guthridge JM; James JA Arthritis Rheum; 2011 Dec; 63(12):3931-41. PubMed ID: 22127709 [TBL] [Abstract][Full Text] [Related]
10. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab. Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220 [TBL] [Abstract][Full Text] [Related]
11. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes. López P; Scheel-Toellner D; Rodríguez-Carrio J; Caminal-Montero L; Gordon C; Suárez A Rheumatology (Oxford); 2014 Dec; 53(12):2249-58. PubMed ID: 24942493 [TBL] [Abstract][Full Text] [Related]
12. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Ju S; Zhang D; Wang Y; Ni H; Kong X; Zhong R Clin Biochem; 2006 Dec; 39(12):1131-7. PubMed ID: 17069785 [TBL] [Abstract][Full Text] [Related]
13. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Becker-Merok A; Nikolaisen C; Nossent HC Lupus; 2006; 15(9):570-6. PubMed ID: 17080911 [TBL] [Abstract][Full Text] [Related]
14. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Roschke V; Wu Y; Baker KP; Hilbert DM Ann Rheum Dis; 2004 Sep; 63(9):1096-103. PubMed ID: 15308519 [TBL] [Abstract][Full Text] [Related]
15. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280 [TBL] [Abstract][Full Text] [Related]
16. BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation. Elbirt D; Asher I; Mahlab-Guri K; Bezalel-Rosenberg S; Edelstein V; Sthoeger Z Isr Med Assoc J; 2014 Aug; 16(8):491-6. PubMed ID: 25269340 [TBL] [Abstract][Full Text] [Related]
17. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Cheema GS; Roschke V; Hilbert DM; Stohl W Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690 [TBL] [Abstract][Full Text] [Related]
18. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Kawasaki A; Tsuchiya N; Fukazawa T; Hashimoto H; Tokunaga K Genes Immun; 2002 Nov; 3(7):424-9. PubMed ID: 12424625 [TBL] [Abstract][Full Text] [Related]
19. Preliminary clinical measurement of the expression of B-cell activating factor in Chinese systemic lupus erythematosus patients. Lin Z; Dan-Rong Y; Xiao-Qing T; Hao W; Hong-Lian G; Xian-Tao K; Ren-Qian Z; Jiyu L J Clin Lab Anal; 2007; 21(3):183-7. PubMed ID: 17506477 [TBL] [Abstract][Full Text] [Related]
20. The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus. Cheng Y; Yan S; Zhao W; Huang Q; Lian L; Wei W Scand J Clin Lab Invest; 2013 Mar; 73(2):141-7. PubMed ID: 23336587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]